Background and objective: It is unknown whether oesophageal disease is associated with systemic sclerosis-associated interstitial lung disease (SSc-ILD) severity, progression or mortality. Methods: High-resolution computed tomography (HRCT) scans from 145 SSc-ILD patients were scored for fibrosis score, oesophageal diameter and presence of hiatal hernia. Fibrosis asymmetry was calculated as: (most affected side − least affected side)/(most affected side + least affected side). Mixed effects models were used for repeated measures analyses. Results: Mean fibrosis score was 8.6%, and most patients had mild-to-moderate physiological impairment. Every 1 cm increase in oesophageal diameter was associated with 1.8% higher fibrosis score and 5.5% lower forced vital capacity (FVC; P ≤ 0.001 for unadjusted and adjusted analyses). Patients with hiatal hernia had 3.9% higher fibrosis score, with persistent differences on adjusted analysis (P = 0.001). Oesophageal diameter predicted worsening fibrosis score over the subsequent year (P = 0.02), but not when adjusting for baseline fibrosis score (P = 0.16). Oesophageal diameter was independently associated with mortality (P = 0.001). Oesophageal diameter was not associated with asymmetric disease or radiological features of gross aspiration. Conclusion: Oesophageal diameter and hiatal hernia are independently associated with SSc-ILD severity and mortality, but not with ILD progression or asymmetric disease. Oesophageal disease is unlikely to be a significant driver of ILD progression in SSc.
INTRODUCTION
Systemic sclerosis (SSc) is an autoimmune connective tissue disease that is characterized by overproduction of collagen and deposition of connective tissue in many organs. 1 Pulmonary involvement is common in SSc, including pulmonary arterial hypertension and interstitial lung disease (ILD), with ILD prevalence ranging from 25 to 90% depending on the criteria used to define ILD. 2, 3 ILD is a major contributor to morbidity and is the most common cause of mortality in patients with SSc. 4 Gastrointestinal tract involvement is present in up to 90% of SSc patients, [5] [6] [7] with the oesophagus most frequently affected. 8 In patients with SSc, oesophageal smooth muscle is replaced by fibrous tissue leading to reflux of gastric contents across an incompetent lower oesophageal sphincter. 9, 10 In patients with idiopathic pulmonary fibrosis (IPF), gastro-oesophageal reflux may be related to initiation and progression of ILD 11, 12 ; however, there is a paucity of longitudinal studies examining whether oesophageal disease influences the development or progression of SSc-ILD. The objectives of this study were to determine the association between oesophageal diameter and SSc-ILD severity, rate of progression and mortality.
SUMMARY AT A GLANCE
We used a large cohort of patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) to conduct the most comprehensive study to date evaluating the association of oesophageal measures with progression and mortality of SSc-ILD. We show that oesophageal disease is associated with SSc-ILD severity and mortality, but not with ILD progression or asymmetry.
METHODS

Study population
Patients with SSc-ILD were recruited from a specialized ILD centre between February 1998 and June 2014. All patients provided written informed consent (University of British Columbia ethics board approval H10-03435). Patients included in the study had an American College of Rheumatology diagnosis of SSc made by a rheumatologist, 1 and fibrotic ILD on a high-resolution computed tomography (HRCT) scan that was available for retrospective analysis. There were no exclusion criteria.
HRCT measurements
Each HRCT was independently reviewed by 1 of 4 fellowship trained cardiothoracic radiologists (C.J.H., D.M., J.S. and N.S.) with 11, 9, 6 and 6 years of experience, respectively. HRCT were scored annually for the first 3 years after SSc-ILD diagnosis when available, then every 3 years until death or censoring. Each lung was divided into three anatomical zones: upper (above right superior pulmonary vein ostia), middle (right superior pulmonary vein ostia to lower margin of right inferior pulmonary vein) and lower (below the lower margin of the inferior pulmonary vein) as previously described. 13 The percentage of honeycombing and reticulation within each zone was recorded. HRCT fibrosis score was calculated as the percentage honeycombing plus reticulation averaged among three anatomical zones per lung. Sensitivity analyses included incorporation of ground glass extent into a total ILD score (i.e. fibrosis score + ground glass extent), with similar findings for all analyses (data not shown). Oesophageal diameter was measured as the maximum coronal diameter from thoracic inlet to oesophageal hiatus. 14, 15 In a previous study of normal volunteers, maximal oesophageal diameter (defined as the largest linear measurement of oesophageal air) was 9.7 mm (95%CI: 6.9 to 14.1). 16 Additional measurements included the presence of a hiatal hernia (oesophageal hiatus >1.5 cm and/or gastric structures above the hiatus), tracheal debris (dependent increased attenuation) and mucoid impaction (distal airways completely occluded by presumed mucous).
Extent of HRCT fibrosis asymmetry was calculated as: (most affected side − least affected side)/(most affected side + least affected side). 11 Complete symmetry is defined as a ratio of 0, whereas a value of 1 indicates strictly unilateral fibrosis. A value of 0.2 was used to define asymmetric disease as previously described, indicating that fibrosis score was 50% higher in the most affected lung compared to the least affected lung.
Other measurements
Baseline data from the date of diagnosis were obtained from the patient record, including age, gender, smoking status and cumulative smoking pack-years. The date of diagnosis was defined as the first HRCT evidence of a fibrotic ILD. Pulmonary function tests were completed according to established guidelines approximately every 6 months as clinically indicated, including spirometry (forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV 1 )), lung volumes, and diffusion capacity of the lung for carbon monoxide (DL CO ) unadjusted for haemoglobin. [17] [18] [19] A detailed serology panel was available for most patients (132/145, 90%) and included anti-nuclear antibodies (ANA), antitopoisomerase I antibodies (anti-Scl-70) and anticentromere antibodies. Additional autoantibodies were not analysed given their low frequencies. When clinically indicated, right ventricular systolic pressure (RVSP) was estimated using the velocity of the tricuspid regurgitant jet on echocardiography, and a 6-min walk distance (6MWD) was measured according to standard recommendations. 20 
Statistical analysis
The association between baseline characteristics and baseline oesophageal diameter, hiatal hernia and HRCT asymmetry was calculated using a chi-square test, Wilcoxon rank sum test or Spearman's rank-order correlation (r value) as appropriate. Progression was defined in separate analyses as either the change in HRCT fibrosis score or change in FVC over time. Mixed effects models were used for longitudinal analyses, including determination of the rate of change of oesophageal diameter over time and the predictors of SSc-ILD progression. Cox proportional hazards regression was used to identify predictors of time to death. Multivariate analyses were conducted for all comparisons to evaluate for potential impact of confounders, including adjustment for age, gender, smoking history, serology, pulmonary function values and echocardiography findings. A two-sided P < 0.05 was considered significant for all calculations. All data analysis was performed using STATA 11.2 (StataCorp, College Station, TX, USA).
RESULTS
Patient characteristics at baseline
A total of 395 HRCT scans were analysed from the 145 included patients (Table 1) , with a median of 2 HRCT per patient (range 1-6). At baseline, patients had an average mild restrictive physiology (FVC 77% predicted) and moderate reduction in DL CO (55%pre-dicted). The median HRCT fibrosis score was 6.7% at baseline (interquartile range (IQR) 3.3-10.8). Mean oesophageal diameter was 2.3 cm (SD 0.9; Fig. 1 ). At baseline, there were 30 (21%) patients with a hiatal hernia, 4 (3%) with tracheal debris and 4 (3%) with mucoid impaction. Two patients had both tracheal debris and mucoid impaction. The prevalence of asymmetry was 27% at baseline. The median follow-up duration was 4.0 years, with a total of 39 deaths and a median survival of 11.2 years from the time of SSc-ILD diagnosis.
Association of oesophageal abnormalities with ILD severity
For every 1 cm increase in oesophageal diameter there was a 1.8% increase in HRCT fibrosis score on unadjusted analysis (P = 0.001; Fig. 2A ). This association remained statistically significant with adjustment for age, gender, weight and body mass index (P = 0.001). For every 1 cm increase in oesophageal diameter there was a 5.5% decrease in FVC %predicted on unadjusted analysis (P < 0.001; Fig. 2B ). The association between oesophageal diameter and FVC %pre-dicted remained statistically significant on adjusted analysis (P = 0.001).
The characteristics of the 30 patients with hiatal hernia and 115 patients without hiatal hernia at baseline are summarized in Table 2 . Patients with a hiatal hernia were older, had a greater pack-year smoking history and had a higher RVSP compared to patients without a hiatal hernia. Patients with a hiatal hernia were also less likely to have a positive ANA (64% vs 87%; P = 0.009) and anti-Scl-70 antibody (13% vs 43%; P = 0.008). Baseline fibrosis score was 3.94% higher in patients with a hiatal hernia than those without a hiatal hernia on unadjusted analysis (P = 0.001), and with adjustment for potential confounders (P = 0.002). Baseline FVC %predicted was not associated with the presence of hiatal hernia on unadjusted analysis (P = 0.16).
Association of oesophageal disease with SSc-ILD progression and mortality
A larger oesophageal diameter predicted worsening HRCT fibrosis score over the subsequent year (P = 0.02; Fig. 3 ), but with no association when adjusting for the baseline HRCT fibrosis score at the beginning of each follow-up period (P = 0.16). Similarly, the presence of a hiatal hernia predicted worsening HRCT fibrosis score on unadjusted analysis (P = 0.02), but not with adjustment for baseline HRCT fibrosis score (P = 0.15). The mean rate of decline in FVC was 1.06% per year (95% CI: 0.64 to 1.47%). Oesophageal diameter did not predict worsening FVC %predicted over the subsequent year on unadjusted analysis (P = 0.18).
Oesophageal diameter predicted mortality on unadjusted analysis (hazard ratio 1.36, 95% CI: 1.15 to 1.61, P < 0.001). Mortality was independently associated with oesophageal diameter (hazard ratio 2.46, 95% CI: 1.35 to 4.50, P = 0.003) when adjusting for age, gender, serology, FVC, FEV 1 , DL CO , fibrosis score and RVSP. The presence of a hiatal hernia predicted mortality on unadjusted analysis (P = 0.01), but not with adjustment for HRCT fibrosis score (P = 0.13).
Association of HRCT asymmetry with SSc-ILD severity and progression
The baseline characteristics of the patients with and without asymmetric disease are summarized in Table 3 . The prevalence of asymmetry at baseline was 27% (40/145), with the right side being affected more often than the left (29 vs 11 patients, P = 0.006 for deviation from an equal proportion). There was no association of asymmetry extent with oesophageal diameter (P = 0.55 with asymmetry score measured as a continuous variable, P = 0.07 when asymmetry was dichotomized) or with the presence of hiatal hernia (P = 0.10 with asymmetry measured as a continuous variable, P = 0.32 when asymmetry was dichotomized). There was no association of asymmetry with change in HRCT fibrosis score (P = 0.18), change in FVC (P = 0.27) or mortality (P = 0.56).
DISCUSSION
We used a large cohort of patients with SSc-ILD to conduct the most comprehensive study to date evaluating the association of oesophageal measures with progression and mortality of SSc-ILD. We show that oesophageal diameter independently associated with SSc-ILD severity and mortality, but that markers of oesophageal disease do not predict ILD progression and are not associated with asymmetric disease. In combination, these findings suggest that oesophageal abnormalities are important markers of overall disease activity in SSc-ILD, but that oesophageal disease and aspiration of gastric contents are unlikely to be major drivers of ILD initiation or progression.
Microaspiration secondary to gastro-oesophageal reflux may contribute to progression of IPF. 11, 12 Crosssectional studies have shown that larger oesophageal diameter and worse acid reflux are associated with the presence of radiographic ILD and worse lung function Oesophageal diameter and SSc-ILD severity in patients with SSc. 21, 22 A previous study showed that higher bronchoalveolar lavage (BAL) pepsin levels predicted acute exacerbation of IPF, and that BAL pepsin levels were higher during acute exacerbation compared to non-exacerbated IPF. 12 A second retrospective study reported that gastro-oesophageal reflux is more common in patients with asymmetric IPF, and that patients with asymmetric IPF were more likely to have acute exacerbation compared to symmetric IPF. 11 Taken together, these studies suggest that disease progression may be related to gastro-oesophageal reflux in some patients with IPF. Unlike previous IPF studies, which have not been replicated to date, we show that oesophageal diameter does not independently predict the rate of fibrosis progression in SSc-ILD, suggesting that oesophageal disease and recurrent aspiration is unlikely to be a significant driver of ILD progression in SSc. This hypothesis is further supported by the near absence of distal markers of macroaspiration in our cohort (tracheal debris and mucoid impaction); recognizing that microaspiration may continue to occur in the absence of these distal markers. It instead appears more likely that the increased oesophageal diameter represents the combination of direct consequences of SSc on the oesophagus as well as tractional oesophageal dilation caused by lower lung fibrosis. These data differ from previous studies that have suggested a role for gastro-oesophageal reflux in the pathogenesis of SSc-ILD. 23 We found that hiatal hernia was both common and associated with baseline fibrosis score in SSc-ILD, although there was no independent association of hiatal hernia with disease progression or mortality. The 21% hiatal hernia prevalence reported in our study was less than the 59% observed in a recent retrospective study of scleroderma patients and the 39-53% prevalence reported in IPF, 24, 25 and is more comparable to the prevalence previously observed in COPD (13%) and asthma (17%). 24 The reasons for these differences with other ILD cohorts are unclear. Similar to our findings related to oesophageal diameter, the association of hiatal hernia with fibrosis score may also be related to direct consequences of SSc on the oesophagus as well as displacement of abdominal structures into the chest as a consequence of relatively negative intrathoracic pressures caused by restrictive lung disease. Despite Figure 2 Unadjusted association of oesophageal diameter with concurrent HRCT fibrosis score (A) and forced vital capacity (FVC) (B).
The slopes and corresponding P values were calculated based on a mixed effects linear model. Data shown are mean (SD) or %. † In total, 57 patients had an echocardiogram at the time of their baseline assessment.
ANA, anti-nuclear antibody; DL CO , diffusion capacity of the lung for carbon monoxide; FEV 1 , forced expiratory volume in 1 s; FVC, forced vital capacity; RVSP, right ventricular systolic pressure; Anti-Scl-70, anti-topoisomerase I antibody.
the robust association of HRCT fibrosis score with structural measures of oesophageal dilation (oesophageal dilation and hiatal hernia), the very low prevalence of distal airway changes suggests that these structural changes were infrequently associated with gross aspiration. Additional larger studies would still be helpful to verify these findings.
Oesophageal diameter may still be an important marker of both pulmonary and extra-pulmonary disease in SSc-ILD despite its inability to independently predict ILD progression. Oesophageal diameter was an independent predictor of time to death in SSc-ILD, indicating that oesophageal diameter may capture additional prognostic information compared to more conventional clinical and laboratory variables. A possible explanation for this association is that oesophageal diameter captures extra-pulmonary disease severity or activity in addition to measuring tractional dilation as a surrogate measure for fibrosis severity. We were unable to evaluate the potential impact of therapy on these outcomes in this retrospective study since patients with progressive disease received therapy and we would be unable to evaluate potential confounding by indication. Similarly, over 95% of patients in our cohort were on anti-acid therapy, prohibiting any analysis on the impact of this therapy. These possibilities require evaluation in future studies. It is also unknown whether oesophageal diameter has prognostic significance in SSc patients who do not have ILD.
The main limitation of this study is that we estimated the severity of oesophageal disease using structural findings of oesophageal diameter and hiatal hernia, and we did not have access to functional measures of gastro-oesophageal reflux or aspiration such as oesophageal manometry or pH monitoring. Previous studies have shown that patients with a hiatal hernia are more likely to have reflux symptoms and overt gastrooesophageal reflux disease compared to those without a hiatal hernia, 26, 27 and that oesophageal dilation on computed tomography scan correlates with oesophageal dysmotility. 28 This strong association of structural variables with functional gastro-oesophageal reflux in previous studies suggests our findings are highly likely to be replicated in future studies using objective functional measures of gastro-oesophageal reflux. This is a retrospective analysis and additional cohorts are required to confirm these findings.
In summary, we used a large cohort of patients with SSc-ILD to show that oesophageal diameter is independently associated with SSc-ILD severity and mortality, but not with ILD progression, asymmetric disease or other radiological markers of gross aspiration. Taken together, these findings suggest that pulmonary fibrosis may have structural consequences on the lower oesophagus in SSc-ILD, but that oesophageal disease has a limited role in ILD initiation or progression. Additional studies are needed to confirm the ability of oesophageal diameter to predict mortality in SSc-ILD and to determine the explanation for this apparently strong association. C.J.R. designed the study, performed the primary analysis and interpretation of the data, and produced the initial draft of the manuscript. All authors contributed to interpretation of data, Figure 3 Unadjusted association of oesophageal diameter with annual rate of change in HRCT fibrosis score. The slope and corresponding P value were calculated based on a mixed effects linear model. 
